U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte ...
"Our focus remains on execution and transparency," said Alfredo Papadakis, CEO of Green Rain Energy Holdings. "As we move our ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is ...
Phase 3 SELVA study evaluating QTORIN rapamycin 3.9% anhydrous gel (QTORIN rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in Ma ...
In preclinical studies, ABP-102 / CT-P72 demonstrated robust antitumor activity in HER2-high tumor models, including dual xenograft models containing both HER2-high and HER2-low tumors, with selective ...
Every successful project starts with a clear road map. Whether you’re launching a new product, revamping your website, or expanding into new markets, ...
Newron's partner EA Pharma Co., Ltd. announces today the initiation of its Phase III clinical trial with evenamide in Japan.
Times-Standard on MSN
Caltrans to close one lane of traffic following flood-related ‘movement’ of Fernbridge
Caltrans has announced a one-day lane closure on Fernbridge scheduled for next week. Drivers can expect 5- to 10-minute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback